Atara Biotherapeutics, Inc. (ATRA) Analysts See $-1.18 EPS

October 14, 2018 - By Vivian Park

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) LogoInvestors sentiment decreased to 1.89 in Q2 2018. Its down 1.97, from 3.86 in 2018Q1. It turned negative, as 11 investors sold Atara Biotherapeutics, Inc. shares while 26 reduced holdings. 19 funds opened positions while 51 raised stakes. 44.51 million shares or 46.45% less from 83.11 million shares in 2018Q1 were reported.
Moreover, Dupont Management has 0.01% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 10,315 shares. Wasatch Advisors accumulated 15,533 shares. 1.46 million were accumulated by Eagle Asset Management. Metropolitan Life Insurance Company Ny holds 13,303 shares or 0% of its portfolio. Daiwa Group reported 208 shares. Susquehanna Gp Ltd Liability Partnership holds 0% or 48,031 shares in its portfolio. Interest Group Inc Inc reported 26,486 shares stake. Hightower Advsr Ltd Limited Liability Company owns 19,059 shares for 0.01% of their portfolio. Fmr Ltd Llc has 0.03% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Retail Bank Of Montreal Can has 4,880 shares. Eaton Vance Management owns 48,806 shares. Price T Rowe Assocs Inc Md has invested 0.01% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Utd Automobile Association holds 8,132 shares. Pacific Heights Asset Mgmt holds 125,000 shares or 0.47% of its portfolio. Swiss Bankshares accumulated 52,600 shares or 0% of the stock.

Since April 11, 2018, it had 1 insider purchase, and 20 insider sales for $9.22 million activity. Porter Derrell also sold $61,992 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares. $1.29M worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was sold by Clark Mitchall G.. Shares for $350,637 were sold by Ciechanover Isaac E. on Wednesday, May 9. Gallagher Carol Giltner had sold 273 shares worth $12,574. $73,600 worth of stock was bought by Koppikar Utpal on Friday, July 27. $535,301 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares were sold by Fust Matthew K.

Analysts expect Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to report $-1.18 EPS on November, 8.They anticipate $0.16 EPS change or 15.69 % from last quarter’s $-1.02 EPS. After having $-1.15 EPS previously, Atara Biotherapeutics, Inc.’s analysts see 2.61 % EPS growth. The stock increased 2.48% or $0.88 during the last trading session, reaching $36.42. About 340,680 shares traded. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has risen 165.68% since October 14, 2017 and is uptrending. It has outperformed by 150.06% the S&P500.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $1.65 billion. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cell's ability to target specific viral proteins implicated in disease.

Another recent and important Atara Biotherapeutics, Inc. (NASDAQ:ATRA) news was published by which published an article titled: “Atara: Forecasting The Upcoming Clinical Binary Of Tab-Cel” on October 08, 2018.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.